David Asuzu1,2, Grégoire P Chatain2,3, Christina Hayes3, Sarah Benzo3, Raven McGlotten4, Meg Keil5, Andrea Beri6, Susmeeta T Sharma7, Lynnette Nieman4, Maya Lodish5, Constantine Stratakis5, Russell R Lonser8, Edward H Oldfield9, Prashant Chittiboina2,3. 1. Yale School of Medicine, New Haven, Connecticut 06510. 2. Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland 20824. 3. Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland 20824. 4. Section on Clinical Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland 20847. 5. Section on Endocrinology and Genetics, Developmental Endocrinology Branch, and Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20847. 6. NIH Biomedical Translational Research Information System, National Institutes of Health Clinical Center, Bethesda, Maryland 20814. 7. Pituitary Endocrinology Section, MedStar Washington Hospital Center, Washington, DC 20010. 8. Department of Neurologic Surgery, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43202. 9. Department of Neurosurgery, University of Virginia School of Medicine, Charlottesville, Virginia 22908.
Abstract
Context: Perioperative increases in adrenocorticotropic hormone (ACTH) and cortisol mimic results of corticotropin-releasing hormone (CRH) stimulation testing. This phenomenon may help identify patients with residual adenoma after transsphenoidal surgery (TSS) for Cushing disease (CD). Objective: To predict nonremission after TSS for CD. Design: Retrospective case-control study of patients treated at a single center from December 2003 until July 2016. Early and medium-term remission were assessed at 10 days and 11 months. Patients and Setting: Two hundred and ninety-one consecutive TSS cases from 257 patients with biochemical evidence of CD seen at a clinical center. Interventions: Normalized early postoperative values (NEPVs) for cortisol and ACTH were calculated as immediate postoperative cortisol or ACTH levels minus preoperative post-CRH-stimulation test levels. Main Outcome Measures: Prediction of early nonremission was evaluated using logistic regression. Prediction of medium-term remission was assessed using Cox regression. Predictive ability was quantified by area under the receiver operating characteristic curve (AUROC). Results: NEPVs for cortisol and ACTH predicted early nonremission [adjusted odds ratio (OR): 1.1; 95% confidence interval (CI): 1.0, 1.1; P = 0.016 and adjusted OR: 1.0; 95% CI: 1.0, 1.0; P = 0.048, respectively]. AUROC for NEPV of cortisol was 0.78 (95% CI: 0.61, 0.95); for NEPV of ACTH, it was 0.80 (95% CI: 0.61, 0.98). NEPVs for cortisol and ACTH predicted medium-term nonremission [hazard ratio (HR): 1.1; 95% CI: 1.0, 1.1; P = 0.023 and HR: 1.0; 95% CI: 1.0, 1.0; P = 0.025, respectively]. Conclusions: NEPVs for cortisol and ACTH predicted nonremission after TSS for CD.
Context: Perioperative increases in adrenocorticotropic hormone (ACTH) and cortisol mimic results of corticotropin-releasing hormone (CRH) stimulation testing. This phenomenon may help identify patients with residual adenoma after transsphenoidal surgery (TSS) for Cushing disease (CD). Objective: To predict nonremission after TSS for CD. Design: Retrospective case-control study of patients treated at a single center from December 2003 until July 2016. Early and medium-term remission were assessed at 10 days and 11 months. Patients and Setting: Two hundred and ninety-one consecutive TSS cases from 257 patients with biochemical evidence of CD seen at a clinical center. Interventions: Normalized early postoperative values (NEPVs) for cortisol and ACTH were calculated as immediate postoperative cortisol or ACTH levels minus preoperative post-CRH-stimulation test levels. Main Outcome Measures: Prediction of early nonremission was evaluated using logistic regression. Prediction of medium-term remission was assessed using Cox regression. Predictive ability was quantified by area under the receiver operating characteristic curve (AUROC). Results: NEPVs for cortisol and ACTH predicted early nonremission [adjusted odds ratio (OR): 1.1; 95% confidence interval (CI): 1.0, 1.1; P = 0.016 and adjusted OR: 1.0; 95% CI: 1.0, 1.0; P = 0.048, respectively]. AUROC for NEPV of cortisol was 0.78 (95% CI: 0.61, 0.95); for NEPV of ACTH, it was 0.80 (95% CI: 0.61, 0.98). NEPVs for cortisol and ACTH predicted medium-term nonremission [hazard ratio (HR): 1.1; 95% CI: 1.0, 1.1; P = 0.023 and HR: 1.0; 95% CI: 1.0, 1.0; P = 0.025, respectively]. Conclusions: NEPVs for cortisol and ACTH predicted nonremission after TSS for CD.
Authors: E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux Journal: N Engl J Med Date: 1991-09-26 Impact factor: 91.245
Authors: M Grino; F Boudouresque; B Conte-Devolx; G Gunz; F Grisoli; C Oliver; P Jaquet Journal: J Clin Endocrinol Metab Date: 1988-04 Impact factor: 5.958
Authors: Leonie H A Broersen; Nienke R Biermasz; Wouter R van Furth; Friso de Vries; Marco J T Verstegen; Olaf M Dekkers; Alberto M Pereira Journal: Pituitary Date: 2018-10 Impact factor: 4.107
Authors: Amro Qaddoura; Tenzin N Shalung; Michael P Meier; Jeannette Goguen; Rowan Jing; Stanley Zhang; Kalman Kovacs; Michael D Cusimano Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Sayoa Eulate-Beramendi; Ainhoa Casajús; Lola Ollero; Lynnette K Niemann; Juan Carlos Fernández-Miranda; Michaël Bruneau; Moncef Berhouma; Luigi Maria Cavallo; Jan Frederick Cornelius; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Ekkehard Kasper; Diego Mazzatenta; Torstein R Meling; Mahmoud Messerer; Henry W S Schroeder; Marcos Tatagiba; Massimiliano Visocchi; Eduard H Voormolen; Idoya Zazpe Journal: Brain Spine Date: 2022-08-07